Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000289969 encodes a long non-coding RNA transcript that is transcribed antisense to the NFIB gene. Natural antisense transcripts like this are typically not translated into protein but can regulate the expression of the overlapping sense gene through diverse mechanisms, including transcriptional interference, RNA duplex formation, and epigenetic modification. While the NFIB gene encodes a transcription factor involved in cell differentiation and cancer, the functional significance of this specific antisense transcript has not been experimentally determined[4]. There are no known drug interactions or clinical applications related to this transcript.
None established; generally, antisense lncRNAs can modulate sense gene expression through transcriptional interference, RNAi mechanisms, or chromatin remodeling, but this is not demonstrated for this transcript[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to NFIB (ENSG00000289969).